Answers are grounded in this paper and cite their sources.
Cigarette smoking is a major yet often underappreciated contributor to liver injury across a broad spectrum of liver diseases. Beyond its well-known systemic toxicity, accumulating evidence demonstrates that tobacco exposure induces hepatocellular damage through excessive oxidative stress, mitochondrial dysfunction, chronic inflammation, immune dysregulation, and genotoxicity. These processes not only initiate liver injury but also synergize with key hepatic risk factors - including hepatitis B virus and hepatitis C virus infections, metabolic dysfunction, and alcohol use - to accelerate progression from steatosis and steatohepatitis to fibrosis, cirrhosis, and hepatocellular carcinoma. Epidemiologic studies, large national cohort studies, and Mendelian randomization analyses identify smoking as an independent and dose-dependent risk factor for metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, viral hepatitis-related complications, advanced fibrosis, liver cancer, and adverse posttransplant outcomes. Despite variability in the strength of evidence across different liver diseases, smoking remains insufficiently recognized in routine hepatology practice, and its hepatic consequences are frequently overshadowed by other risk factors. Integrating standardized smoking assessment and cessation interventions into liver disease management may substantially reduce disease progression and liver-related mortality. Meanwhile, important knowledge gaps persist regarding the histologic reversibility of smoking-related injury, the long-term legacy effects of smoking, and the hepatic toxicity of emerging products such as e-cigarettes. Addressing these gaps is essential for developing evidence-based clinical strategies and public health policies.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: